Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Medicine
Published in: BMC Medicine 1/2022

Open Access 01-12-2022 | Breast Cancer | Forum

The impact of race and ethnicity in breast cancer—disparities and implications for precision oncology

Authors: Kelly A. Hirko, Gabrielle Rocque, Erica Reasor, Ammanuel Taye, Alex Daly, Ramsey I. Cutress, Ellen R. Copson, Dae-Won Lee, Kyung-Hun Lee, Seock-Ah Im, Yeon Hee Park

Published in: BMC Medicine | Issue 1/2022

Login to get access

Abstract

Breast cancer is the most commonly diagnosed cancer worldwide and is one of the leading causes of cancer death. The incidence, pathological features, and clinical outcomes in breast cancer differ by geographical distribution and across racial and ethnic populations. Importantly, racial and ethnic diversity in breast cancer clinical trials is lacking, with both Blacks and Hispanics underrepresented. In this forum article, breast cancer researchers from across the globe discuss the factors contributing to racial and ethnic breast cancer disparities and highlight specific implications of precision oncology approaches for equitable provision of breast cancer care to improve outcomes and address disparities.
Literature
1.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.PubMedCrossRef
2.
Zavala VA, Bracci PM, Carethers JM, Carvajal-Carmona L, Coggins NB, Cruz-Correa MR, et al. Cancer health disparities in racial/ethnic minorities in the United States. Br J Cancer. 2021;124:315–32.PubMedCrossRef
3.
Gomez SL, Noone A-M, Lichtensztajn DY, Scoppa S, Gibson JT, Liu L, et al. Cancer incidence trends among Asian American populations in the United States, 1990-2008. J Natl Cancer Inst. 2013;105:1096–110.PubMedPubMedCentralCrossRef
4.
Pinheiro PS, Sherman RL, Trapido EJ, Fleming LE, Huang Y, Gomez-Marin O, et al. Cancer incidence in first generation U.S. Hispanics: Cubans, Mexicans, Puerto Ricans, and new Latinos. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2009;18:2162–9.CrossRef
5.
Brinton LA, Gaudet MM, Gierach GL. Breast cancer. In: Thun M, Linet MS, Cerhan JR, Haiman CA, Schottenfeld D, editors. Cancer epidemiology and prevention. Oxford: Oxford University Press; 2018. p. 861–88.
6.
Ellis L, Canchola AJ, Spiegel D, Ladabaum U, Haile R, Gomez SL. Racial and ethnic disparities in cancer survival: the contribution of tumor, sociodemographic, institutional, and neighborhood characteristics. J Clin Oncol Off J Am Soc Clin Oncol. 2018;36:25–33.CrossRef
7.
Sparano JA, Brawley OW. Deconstructing racial and ethnic disparities in breast cancer. JAMA Oncol. 2021;7:355–6.PubMedCrossRef
8.
Lundqvist A, Andersson E, Ahlberg I, Nilbert M, Gerdtham U. Socioeconomic inequalities in breast cancer incidence and mortality in Europe-a systematic review and meta-analysis. Eur J Public Health. 2016;26:804–13.PubMedPubMedCentralCrossRef
9.
10.
Shariff-Marco S, Yang J, John EM, Kurian AW, Cheng I, Leung R, et al. Intersection of race/ethnicity and socioeconomic status in mortality after breast cancer. J Community Health. 2015;40:1287–99.PubMedPubMedCentralCrossRef
11.
Linnenbringer E, Geronimus AT, Davis KL, Bound J, Ellis L, Gomez SL. Associations between breast cancer subtype and neighborhood socioeconomic and racial composition among Black and White women. Breast Cancer Res Treat. 2020;180:437–47.PubMedPubMedCentralCrossRef
12.
Aldrighetti CM, Niemierko A, Van Allen E, Willers H, Kamran SC. Racial and ethnic disparities among participants in precision oncology clinical studies. JAMA Netw Open. 2021;4:e2133205.PubMedPubMedCentralCrossRef
13.
Metcalfe KA, Poll A, Royer R, Llacuachaqui M, Tulman A, Sun P, et al. Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28:387–91.CrossRef
14.
Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295:2492–502.PubMedCrossRef
15.
Pan J-W, Zabidi MMA, Ng P-S, Meng M-Y, Hasan SN, Sandey B, et al. The molecular landscape of Asian breast cancers reveals clinically relevant population-specific differences. Nat Commun. 2020;11:6433.PubMedPubMedCentralCrossRef
16.
Serrano-Gómez SJ, Fejerman L, Zabaleta J. Breast cancer in Latinas: a focus on intrinsic subtypes distribution. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2018;27:3–10.CrossRef
17.
Stringer-Reasor EM, May JE, Olariu E, Caterinicchia V, Li Y, Chen D, et al. An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer. Breast Cancer Res BCR. 2021;23:30.PubMedCrossRef
18.
Reeder-Hayes K, Peacock Hinton S, Meng K, Carey LA, Dusetzina SB. Disparities in use of human epidermal growth hormone receptor 2-targeted therapy for early-stage breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34:2003–9.CrossRef
19.
Borrell LN, Elhawary JR, Fuentes-Afflick E, Witonsky J, Bhakta N, Wu AHB, et al. Race and genetic ancestry in medicine - a time for reckoning with racism. N Engl J Med. 2021;384:474–80.PubMedCrossRef
20.
Ioannidis JPA, Powe NR, Yancy C. Recalibrating the use of race in medical research. JAMA. 2021;325:623–4.PubMedCrossRef
21.
Flanagin A, Frey T, Christiansen SL, AMA Manual of Style Committee. Updated guidance on the reporting of race and ethnicity in medical and science journals. JAMA. 2021;326:621–7.PubMedCrossRef
22.
23.
Yedjou CG, Tchounwou PB, Payton M, Miele L, Fonseca DD, Lowe L, et al. Assessing the racial and ethnic disparities in breast cancer mortality in the United States. Int J Environ Res Public Health. 2017;14(5):486.PubMedCentralCrossRef
24.
25.
Hagerty RG, et al. Communicating with realism and hope: incurable cancer patients’ views on the disclosure of prognosis. J Clin Oncol. 2005;23(6):1278–88.PubMedCrossRef
26.
Stringer-Reasor EM, et al. Disparities in breast cancer associated with African American identity. Am Soc Clin Oncol Educ Book. 2021;41:e29–46.PubMedCrossRef
27.
28.
Henderson LM, O’Meara ES, Haas JS, Lee CI, Kerlikowske K, Sprague BL, et al. The role of social determinants of health in self-reported access to health care among women undergoing screening mammography. J Womens Health. 2020;29(11):1437–46.CrossRef
29.
Wheeler SB, Reeder-Hayes KE, Carey LA. Disparities in breast cancer treatment and outcomes: biological, social, and health system determinants and opportunities for research. Oncologist. 2013;18(9):986–93.PubMedPubMedCentralCrossRef
30.
Bickell NA, Wang JJ, Oluwole S, Schrag D, Godfrey H, Hiotis K, et al. Missed opportunities: racial disparities in adjuvant breast cancer treatment. J Clin Oncol. 2006;24(9):1357–62.PubMedCrossRef
31.
Smith GL, Shih Y-CT, Xu Y, Giordano SH, Smith BD, Perkins GH, et al. Racial disparities in the use of radiotherapy after breast-conserving surgery: a national Medicare study. Cancer. 2010;116(3):734–41.PubMedCrossRef
32.
33.
Winkfield KM, et al. Addressing equity, diversity, and inclusion of Black physicians in the oncology workforce. JCO Oncol Pract. 2021;17(5):224–6.CrossRef
34.
Tucker-Seeley RD. Social determinants of health and disparities in cancer care for Black people in the United States. JCO Oncol Pract. 2021;17(5):261–3.PubMedCrossRef
35.
Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Smith LV, et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat. 2008;109(1):123–39.PubMedCrossRef
36.
Ooi SL, Martinez ME, Li CI. Disparities in breast cancer characteristics and outcomes by race/ethnicity. Breast Cancer Res Treat. 2011;127(3):729–38.PubMedCrossRef
37.
Siegel RL, et al. Cancer statistics for Hispanics/Latinos, 2015. CA Cancer J Clin. 2015;65(6):457–80.PubMedCrossRef
38.
Adedokun B, et al. Prevalence of inherited mutations in breast cancer predisposition genes among women in Uganda and Cameroon. Cancer Epidemiol Biomarkers Prev. 2020;29(2):359–67.PubMedCrossRef
39.
40.
Felix GES, et al. BROCA gene panel testing in African descendants from northeastern Brazil: genetic susceptibility profile of an admixed population. J Clin Oncol. 2017;35(15_suppl):1572.CrossRef
41.
Gomez SL, et al. Breast cancer in Asian Americans in California, 1988–2013: increasing incidence trends and recent data on breast cancer subtypes. Breast Cancer Res Treat. 2017;164(1):139–47.PubMedPubMedCentralCrossRef
42.
Aizer AA, et al. Lack of reduction in racial disparities in cancer-specific mortality over a 20-year period. Cancer. 2014;120(10):1532–9.PubMedCrossRef
43.
Pitt JJ, et al. Characterization of Nigerian breast cancer reveals prevalent homologous recombination deficiency and aggressive molecular features. Nat Commun. 2018;9(1):4181.PubMedPubMedCentralCrossRef
44.
Weitzel JN, et al. Prevalence of BRCA mutations and founder effect in high-risk Hispanic families. Cancer Epidemiol Biomarkers Prev. 2005;14(7):1666–71.PubMedCrossRef
45.
Chen CH, et al. Disparity in tumor immune microenvironment of breast cancer and prognostic impact: Asian versus Western populations. Oncologist. 2020;25(1):e16–23.PubMedCrossRef
46.
U.S. Cancer Statistics Working Group. U.S. Cancer Statistics Data Visualizations Tool, based on 2019 submission data (1999-2017): U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2020. Available from: www.​cdc.​gov/​cancer/​dataviz.
47.
48.
Loree JM, Anand S, Dasari A, Unger JM, Gothwal A, Ellis LM, et al. Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018. JAMA Oncol. 2019;5(10):e191870.PubMedPubMedCentralCrossRef
49.
50.
Copson E, Maishman T, Gerty S, et al. Ethnicity and outcome of young breast cancer patients in the United Kingdom: the POSH study. Br J Cancer. 2014;110(1):230–41.PubMedCrossRef
51.
52.
Jemal A, Robbins AS, Lin CC, et al. Factors that contributed to Black-White disparities in survival among nonelderly women with breast cancer between 2004 and 2013. J Clin Oncol. 2018;36(1):14–24.PubMedCrossRef
53.
Gathani T, Ali R, Balkwill A, et al. Ethnic differences in breast cancer incidence in England are due to differences in known risk factors for the disease: prospective study. Br J Cancer. 2014;110(1):224–9.PubMedCrossRef
54.
Smigal C, Jemal A, Ward E, et al. Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J Clin. 2006;56(3):168–83.PubMedCrossRef
55.
Desantis C, Ma J, Bryan L, et al. Breast cancer statistics, 2013. CA Cancer J Clin. 2014;64(1):52–62.PubMedCrossRef
56.
Stapleton SM, Oseni TO, Bababekov YJ, et al. Race/ethnicity and age distribution of breast cancer diagnosis in the United States. JAMA Surg. 2018;153(6):594.PubMedPubMedCentralCrossRef
57.
58.
Shoemaker ML, White MC, Wu M, et al. Differences in breast cancer incidence among young women aged 20–49 years by stage and tumor characteristics, age, race, and ethnicity, 2004–2013. Breast Cancer Res Treat. 2018;169(3):595–606.PubMedPubMedCentralCrossRef
59.
Jones CEL, Maben J, Jack RH, et al. A systematic review of barriers to early presentation and diagnosis with breast cancer among black women. BMJ Open. 2014;4(2):e004076.PubMedPubMedCentralCrossRef
60.
Copson ER, Maishman TC, Tapper WJ, et al. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. Lancet Oncol. 2018;19(2):169–80.PubMedPubMedCentralCrossRef
61.
Gathani T, Chiuri K, Broggio J, et al. Ethnicity and the surgical management of early invasive breast cancer in over 164 000 women. Br J Surg. 2021;108(5):528–33.PubMedPubMedCentralCrossRef
62.
Pinder RJ, Ferguson J, Møller H. Minority ethnicity patient satisfaction and experience: results of the National Cancer Patient Experience Survey in England. BMJ Open. 2016;6(6):e011938.PubMedPubMedCentralCrossRef
63.
Reeder-Hayes KE, Meyer AM, Dusetzina SB, et al. Racial disparities in initiation of adjuvant endocrine therapy of early breast cancer. Breast Cancer Res Treat. 2014;145(3):743–51.PubMedPubMedCentralCrossRef
64.
Iqbal J, Ginsburg O, Rochon PA, et al. Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States. JAMA. 2015;313(2):165.PubMedCrossRef
65.
66.
International Health Conference. Constitution of the World Health Organization- 1946. Bull World Health Organ. 2002;80(12):983–4.
67.
Lin CH, Yap YS, Lee KH, Im SA, Naito Y, Yeo W, et al. Contrasting epidemiology and clinicopathology of female breast cancer in Asians vs the US population. J Natl Cancer Inst. 2019;111:1298–306.PubMedPubMedCentralCrossRef
68.
Yap YS, Lu YS, Tamura K, Lee JE, Ko EY, Park YH, et al. Insights into breast cancer in the east vs the west: a review. JAMA Oncol. 2019;5:1489–96.PubMedCrossRef
69.
Szostakowska M, Trebinska-Stryjewska A, Grzybowska EA, Fabisiewicz A. Resistance to endocrine therapy in breast cancer: molecular mechanisms and future goals. Breast Cancer Res Treat. 2019;173:489–97.PubMedCrossRef
70.
Lee KWC, Lord S, Finn RS, Lim E, Martin A, Loi S, et al. The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis. Breast Cancer Res Treat. 2019;174:271–8.PubMedCrossRef
71.
Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35:2875–84.PubMedCrossRef
72.
Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018;36:2465–72.PubMedCrossRef
73.
Im SA, Mukai H, Park IH, Masuda N, Shimizu C, Kim SB, et al. Palbociclib plus letrozole as first-line therapy in postmenopausal Asian women with metastatic breast cancer: results from the phase III, randomized PALOMA-2 Study. J Glob Oncol. 2019;5:1–19.PubMed
74.
Iwata H, Im SA, Masuda N, Im YH, Inoue K, Rai Y, et al. PALOMA-3: phase III trial of fulvestrant with or without palbociclib in premenopausal and postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer that progressed on prior endocrine therapy-safety and efficacy in Asian patients. J Glob Oncol. 2017;3:289–303.PubMedPubMedCentralCrossRef
75.
Toi M, Inoue K, Masuda N, Iwata H, Sohn J, Hae Park I, et al. Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2- advanced breast cancer: MONARCH 2 & 3 trials. Cancer Sci. 2021;112:2381–92.PubMedPubMedCentralCrossRef
76.
Im SA, Yap YS, Sohn J, Lee KS, Jung KH, Tseng LM, et al. Pooled analysis of efficacy and safety in Asian patients (pts) in the MONALEESA-2, MONALEESA-3, and MONALEESA-7 trials of ribociclib (RIB) plus endocrine therapy (ET). Ann Oncol. 2019;30:ix15 (conference abstract).
77.
Burris HA, Chan A, Bardia A, Thaddeus Beck J, Sohn J, Neven P, et al. Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer. Br J Cancer. 2021;125:679–86.PubMedCrossRef
78.
79.
Yamaori S, Yamazaki H, Iwano S, Kiyotani K, Matsumura K, Saito T, et al. Ethnic differences between Japanese and Caucasians in the expression levels of mRNAs for CYP3A4, CYP3A5 and CYP3A7: lack of co-regulation of the expression of CYP3A in Japanese livers. Xenobiotica. 2005;35:69–83.PubMedCrossRef
80.
81.
DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A, et al. Breast cancer statistics, 2019. CA Cancer J Clin. 2019;69(6):438–51.PubMedCrossRef
82.
Winter C, Nilsson MP, Olsson E, George AM, Chen Y, Kvist A, et al. Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic. Ann Oncol. 2016;27(8):1532–8.PubMedPubMedCentralCrossRef
83.
Atchley DP, Albarracin CT, Lopez A, Valero V, Amos CI, Gonzalez-Angulo AM, et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol. 2008;26(26):4282–8.PubMedPubMedCentralCrossRef
84.
Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D, Nevanlinna H, et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev. 2012;21(1):134–47.PubMedCrossRef
85.
Couch FJ, Hart SN, Sharma P, Toland AE, Wang X, Miron P, et al. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol. 2015;33(4):304–11.PubMedCrossRef
86.
Im SA, Xu B, Li W, Robson M, Ouyang Q, Yeh DC, et al. Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis. Sci Rep. 2020;10(1):8753.PubMedPubMedCentralCrossRef
87.
Park S, Lee E, Park S, Lee S, Nam SJ, Kim SW, et al. Clinical characteristics and exploratory genomic analyses of germline BRCA1 or BRCA2 mutations in breast cancer. Mol Cancer Res. 2020;18(9):1315–25.PubMedCrossRef
88.
Ryu JM, Choi HJ, Kim I, Nam SJ, Kim SW, Yu J, et al. Prevalence and oncologic outcomes of BRCA 1/2 mutations in unselected triple-negative breast cancer patients in Korea. Breast Cancer Res Treat. 2019;173(2):385–95.PubMedCrossRef
89.
Ryu JM, Kang G, Nam SJ, Kim SW, Yu J, Lee SK, et al. Suggestion of BRCA1 c.5339T>C (p.L1780P) variant confer from ‘unknown significance’ to ‘likely pathogenic’ based on clinical evidence in Korea. Breast. 2017;33:109–16.PubMedCrossRef
90.
Park JS, Nam EJ, Park HS, Han JW, Lee JY, Kim J, et al. Identification of a novel BRCA1 pathogenic mutation in Korean patients following reclassification of BRCA1 and BRCA2 variants according to the ACMG Standards and Guidelines Using Relevant Ethnic Controls. Cancer Res Treat. 2017;49(4):1012–21.PubMedPubMedCentralCrossRef
91.
Park KS, Cho EY, Nam SJ, Ki CS, Kim JW. Comparative analysis of BRCA1 and BRCA2 variants of uncertain significance in patients with breast cancer: a multifactorial probability-based model versus ACMG standards and guidelines for interpreting sequence variants. Genet Med. 2016;18(12):1250–7.PubMedCrossRef
Metadata
Title
The impact of race and ethnicity in breast cancer—disparities and implications for precision oncology
Authors
Kelly A. Hirko
Gabrielle Rocque
Erica Reasor
Ammanuel Taye
Alex Daly
Ramsey I. Cutress
Ellen R. Copson
Dae-Won Lee
Kyung-Hun Lee
Seock-Ah Im
Yeon Hee Park
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Medicine / Issue 1/2022
Electronic ISSN: 1741-7015
DOI
https://doi.org/10.1186/s12916-022-02260-0

Other articles of this Issue 1/2022

BMC Medicine 1/2022 Go to the issue

Research article

Adiposity and grip strength: a Mendelian randomisation study in UK Biobank

Research article

Prioritising attributes for tuberculosis preventive treatment regimens: a modelling analysis

Research article

Rapid elimination of cervical cancer while maintaining the harms and benefits ratio of cervical cancer screening: a modelling study

Review

New strategies to improve clinical outcomes for diabetic kidney disease

Editorial

From screening to treatment: the new landscape of diabetic kidney disease

Research article

Number of standard modifiable risk factors and mortality in patients with first-presentation ST-segment elevation myocardial infarction: insights from China Acute Myocardial Infarction registry